Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 18/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425676 | 0.94 | BDKRB1 (0.56) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4421066 | 0.92 | BDKRB1 (0.56) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4429941 | 0.91 | BDKRB1 (0.56) | BDKRB1ALDH1A1POLB | |
| SCHEMBL6030126 | 0.91 | BDKRB1 (0.59) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4432159 | 0.91 | BDKRB1 (0.59) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4422218 | 0.91 | BDKRB1 (0.55) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4432009 | 0.91 | BDKRB1 (0.55) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4422326 | 0.91 | BDKRB1 (0.53) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4431412 | 0.90 | BDKRB1 (0.52) | BDKRB1ALDH1A1POLB | |
| SCHEMBL4419810 | 0.90 | BDKRB1 (0.55) | BDKRB1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | BDKRB1 2/4885ALDH1A1 2366/4885POLB 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.